Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg

Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg

Introduction<p>Oropharyngeal squamous cell carcinoma (OPC) associated with high-risk human papillomavirus (HPV), particularly HPV-16, generally shows favorable outcomes yet paradoxically exhibits a high incidence of early lymphatic metastasis. The immune mechanisms underlying this phenomenon r...

Saved in:

书目详细资料
主要作者:	Naohiro Wakisaka (407153) (author)
其他作者:	Makiko Moriyama-Kita (833101) (author), Satoru Kondo (407152) (author), Eiji Kobayashi (107710) (author), Takayoshi Ueno (457816) (author), Yosuke Nakanishi (407151) (author), Kazuhira Endo (407155) (author), Hisashi Sugimoto (2146888) (author), Tomokazu Yoshizaki (407160) (author)
出版:	2025
主题:	Oncology and Carcinogenesis not elsewhere classified HPV-positive oropharyngeal cancer palatine tonsil spatial transcriptomics tumor immune microenvironment Th2 immunity lymphatic metastasis eosinophils and mast cells estrogen signaling
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Image 4_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 2_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 3_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Image 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
由: Naohiro Wakisaka (407153)
出版: (2025)

Table 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.xlsx
由: Naohiro Wakisaka (407153)
出版: (2025)

Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
由: Anna Starshinova (22571846)
出版: (2025)

Substrate recognition diversity and transport dynamics of ABCC1
由: Pu Gao (14074898)
出版: (2025)

Supplementary Figure S1 from Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
由: Glenn J. Hanna (15036909)
出版: (2025)

Data Sheet 10_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 9_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 8_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 6_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 7_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 5_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 4_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 3_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 2_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Data Sheet 1_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
由: Huiping Fan (13921872)
出版: (2025)

Microbiome Mediated Immune Crosstalk on the Gut-Thyroid Axis in Autoimmune Thyroid Disease
由: Mubeen Hussein Arawker (12965954)
出版: (2025)

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
由: Seyed Reza Mousavi (13223324)
出版: (2025)

The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
由: Seyed Reza Mousavi (13223324)
出版: (2025)

Survey of dysphagia protocol use (Carnaby et al., 2025)
由: Giselle D. Carnaby (22575401)
出版: (2025)

Image 2_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
由: Yini Wang (410389)
出版: (2025)

Image 1_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
由: Yini Wang (410389)
出版: (2025)

Lipids attribution for controls and dengue groups according with Lipid Maps database, obtained via exploratory metabolomics from human serum.
由: Ricardo E. Correa Fierro (22676430)
出版: (2025)

Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx
由: Mengying Qian (2541466)
出版: (2025)

Table S2 from Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
由: Taohua Yue (14963045)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
由: Yu Chen (1234761)
出版: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
由: Isha Mondal (16721699)
出版: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
由: Kankan Cao (16437263)
出版: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
由: Hansol Lee (15054787)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ge5hodq8dlmtupnj362b0p0gsi